News Related to Dystrophic Epidermolysis Bullosa

Related coverage linked through entity extraction aliases.

Krystal Biotech reports Q1 2026 progress on KB803, KB801 and VYJUVEK expansion

May 04, 2026

Krystal Biotech said IOLITE enrollment for KB803 is complete and it remains on track for KB803 and KB801 registrational data readouts in 2026. The company also reported FDA platform technology designations for KB407 and KB111 and continued VYJUVEK expansion.

Krystal Biotech heads into earnings with Vyjuvek growth and pipeline milestones in focus

Apr 04, 2026

Krystal Biotech is set to report fourth-quarter results with analysts expecting $1.58 a share on $106.16 million in revenue. Investors are watching Vyjuvek growth and pipeline programs including KB801, KB407 and KB707.